Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy

Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy

US Patent 11413340 · Granted Aug 16, 2022

Estimated economic value: $39,265,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Multi-specific antibody constructs2025
Multi-specific antibody constructs2025
Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconj2025
Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconj2025
Chimeric antigen receptors and uses thereof2025
Chimeric antigen receptors and uses thereof2025
CD19 and CD22 chimeric antigen receptors and uses thereof2025
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric a2025
Treatment of cancer using a CD33 chimeric antigen receptor2025
Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereo2025
Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereo2025
Method of assessing the efficacy of a test agent for modulating programmed death2025